{"nctId":"NCT00475878","briefTitle":"SSRI and Buprenorphine","startDateStruct":{"date":"2006-12"},"conditions":["Opiate Dependence","Depression"],"count":147,"armGroups":[{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"escitalopram","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: escitalopram"]}],"interventions":[{"name":"escitalopram","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* opiate dependence\n* Ham-D \\> 14\n\nExclusion Criteria:\n\n* no psychiatric contraindications to using escitalopram\n* no medical contraindications to using escitalopram\n* methadone dose \\< 30\n* no current SSRI use","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Dropped Out of Buprenorphine Treatment","description":"Drop-out is defined as 7 or more days of missed Buprenorphine doses","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":null},{"groupId":"OG001","value":"44.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Depressive Symptoms","description":"Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.31","spread":"1.79"},{"groupId":"OG001","value":"11.35","spread":"1.46"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":75},"commonTop":[]}}}